Journal article

Comparison of F-18-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL (R) approaches: Validation against histopathology

Vincent Dore, Santiago Bullich, Christopher C Rowe, Pierrick Bourgeat, Salamata Konate, Osama Sabri, Andrew W Stephens, Henryk Barthel, Jurgen Fripp, Colin L Masters, Ludger Dinkelborg, Olivier Salvado, Victor L Villemagne, Susan De Santi

ALZHEIMERS & DEMENTIA | ELSEVIER SCIENCE INC | Published : 2019

Abstract

INTRODUCTION: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS: Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy dat..

View full abstract